Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 11,433 matching trials from the live ClinicalTrials.gov search.
Conditions
HIV Infections
Interventions
Abacavir/Lamivudine, Atazanavir, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Ritonavir, Abacavir/Lamivudine placebo, Emtricitabine/Tenofovir disoproxil fumarate placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older
Enrollment
1,864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
51
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 30 more
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, tirapazamine, radiation therapy
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
87
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more
Conditions
Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
397
States / cities
Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 287 more
Conditions
Soft Tissue Sarcoma
Interventions
Palifosfamide-Tris, Doxorubicin
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years to 120 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
18
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Tampa, Florida + 15 more
Conditions
Asthma in Children
Interventions
Improving Asthma Care Together (IMPACT)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
7 Years to 11 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Conditions
HIV, Heart Failure
Interventions
Exercise Intervention, Tailored Education sessions, Behavioral coaching, Mobile health support, General education
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Alpha-1 Antitrypsin Deficiency (AATD)
Interventions
TSRA-196
Drug
Lead sponsor
Tessera Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Jacksonville, Florida • Boston, Massachusetts • Rochester, Minnesota + 2 more
Conditions
Breast Cancer
Interventions
bevacizumab, docetaxel, doxorubicin, cyclophosphamide, pegfilgrastim
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years to 70 Years · Female only
Enrollment
1,613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
522
States / cities
Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 372 more
Completed Not applicable Interventional

Dosing Study of Massage for Neck Pain

NCT01122836
Conditions
Chronic Neck Pain
Interventions
Massage
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
20 Years to 64 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Corticosteroid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
3 Months to 18 Months
Enrollment
1,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
36
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more
Conditions
Relapsed/Refractory Primary Central Nervous System Lymphoma
Interventions
Tirabrutinib, Rituximab, Temozolomide
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
26
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 19 more
Conditions
Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
Biospecimen Collection, Drug Withdrawn, Quality-of-Life Assessment, Questionnaire Administration, Tyrosine Kinase Inhibitor
Procedure · Other · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 25 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
157
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 123 more
Conditions
Chronic Hepatitis B
Interventions
Tenofovir disoproxil fumarate (tenofovir DF; TDF), Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), Entecavir (ETV), TDF placebo, FTC/TDF placebo, ETV placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 69 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 5 more
Conditions
Invasive Fungal Infection
Interventions
Isavuconazonium sulfate, Voriconazole, Posaconazole
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
Not listed
Enrollment
2,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more
Conditions
HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 Gene Mutation
Interventions
ORM-5029
Drug
Lead sponsor
Orum Therapeutics USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 7 more
Conditions
Dermatomyositis
Interventions
Baricitinib
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ruxolitinib phosphate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
24
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 21 more
Conditions
Microtia, Microtia-Anotia, Craniofacial Microsomia, Goldenhar Syndrome, OAVS, OAV Syndrome, Hemifacial Microsomia
Interventions
Not listed
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
0 Years to 18 Years
Enrollment
935 participants
Timeline
2018 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more
Conditions
Leukemia, Myeloid
Interventions
Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
1 Year to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 51 more
Conditions
Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases, Colorectal Neoplasms
Interventions
PF-08634404, Bevacizumab, Chemotherapy
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
254
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 173 more
Conditions
Traumatic Brain Injury, Pain
Interventions
Not listed
Lead sponsor
Craig Hospital
Other
Eligibility
16 Years and older
Enrollment
3,805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
13
States / cities
Birmingham, Alabama • Englewood, Colorado • Tampa, Florida + 10 more
Conditions
Multiple Myeloma
Interventions
Alnuctamab, Pomalidomide, Daratumumab, Elotuzumab, Carfilzomib, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 19 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
placebo, BIBW 2992
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
14
States / cities
Kingman, Arizona • Fayetteville, Arkansas • Anaheim, California + 11 more